:strip_icc()/s04.video.glbimg.com/x720/8904551.jpg)
[ad_1]
Pharmaceutical Union Chemical said on Friday (23) that it has signed an agreement with the Russian Direct Investment Fund (RDIF) to produce the Russian Sputnik V vaccine against Covid-19 from the second half of November.
The company said it has signed a confidentiality agreement that prevents it from providing technical or scientific details. The lab has yet to obtain approval from the National Sanitary Surveillance Agency (Anvisa) for production.
- Anvisa releases import of 6 million doses of CoronaVac, a vaccine against Covid that is in the third phase of testing
- ‘It is up to Brazil to decide which vaccine to buy’, says WHO director general
The agreement signed by the Chemical Union is the second for the production of the Russian vaccine in Brazil, where four other vaccines against Covid-19 are already being tested.
The Russian vaccine is being developed by the Gamaleya Research Institute in Moscow and marketed by RDIF, which last month closed an agreement with the Paraná government to test and produce the vaccine in Brazil.
The government of Bahia also signed an agreement to conduct phase III clinical trials of the Sputnik V vaccine and plans to purchase 50 million doses.
However, it is not clear when these tests can begin.
An Anvisa spokeswoman said the governments of Paraná and Bahia have not yet requested approval of their plans to test the Russian vaccine, let alone produce it.
Russian vaccine begins testing in Belarus
Bahia Health Secretary Fábio Vilas-Boas told Reuters that the Russian sovereign wealth fund and the Gamaleya Institute are negotiating directly with Anvisa regarding previous test data.
With more than 5.3 million confirmed coronavirus cases, Brazil has the world’s third worst outbreak, after the United States and India, making the country a testing ground in the race to find a vaccine.
End-stage trials are underway for the vaccines being developed by the University of Oxford / AstraZeneca; Sinovac Biotech; Pfizer in association with BioNTech; and Johnson & Johnson’s pharmaceutical subsidiary, Janssen.
- Brazil may start Russian vaccine production in December, says investor fund
- The findings of the study on the Russian vaccine against coronavirus
